Prostate specific antigen peptides and uses thereof
AssigneeAbbott Laboratories
InventorsBarry Lee Dowell, Dominique P. Bridon, Xiaoxing Qiu, Hans Lilja, Timo Petteri Piironen, Mauno Antero Vihinen, Kim Sverker Immanuel Pettersson
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides which may be used, for example, in the detection of free and complexed Prostate Specific Antigen and thus in the diagnosis of prostate cancer.
Claims15
An antibody specific for free PSA produced in response to immunization by a peptide selected from the group consisting of ABT6 and ABT1.
An antibody specific for total PSA produced in response to immunization by a peptide selected from the group consisting of ABT14 and ABT16.
A method for detecting PSA in a test sample suspected of containing PSA comprising the steps of:
- a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one site on a peptide or antigen for a time and under conditions sufficient to allow for the formation of antigen/antibody complexes
- wherein said peptide or antigen is selected from the group consisting of ABT2, ABT6, ABT1, ABT7, and ABT16 and said antibody or fragment thereof has been produced in response to said peptide or antigen;
- b) adding a probe antibody to said resulting antigen/antibody complexes for a time and under conditions sufficient to allow said probe to bind to said bound antigen, wherein said probe binds to a second site on said peptide or antigen;
- and
- c) determining the amount of bound probe and thus the amount of PSA in said test sample.
A method of detecting PSA in a test sample suspected of containing PSA comprising the steps of:
- a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one peptide or antigen derived from PSA for a time and under conditions sufficient to allow for formation of antigen/antibody complexes
- wherein said peptide or antigen is selected from the group consisting of ABT2, ABT6, ABT1, ABT7 and ABT16 and said antibody or fragment thereof is produced in response to said peptide or antigen;
- b) adding a labeled free PSA to said resulting test sample-antibody mixture of step (a);
- and
- c) determining the amount of PSA in the test sample by assessing the amount of competition between the PSA in the test sample and the labeled free PSA.
A kit for determining the presence of PSA in a test sample comprising a container containing an antibody produced in response to immunization by a peptide selected from the group consisting of ABT2, ABT6, ABT1, ABT7, and ABT16.
A kit for determining the presence of PSA in a test sample comprising:
- a) an antibody or fragment thereof which specifically binds to at least one site on PSA
- wherein said antibody or fragment thereof is produced in response to immunization by a peptide consisting essentially of an amino acid sequence of approximately 10-20 residues wherein said sequence is identical to the amino acid sequence of a region of PSA and consists essentially of one or more amino acids non-identical to the amino acid sequence of hk2, wherein said peptide is selected from the group consisting of ATB2, ABT6, ABT1, ABT7, and ABT16;
- and
- b) a probe antibody wherein said probe binds to a second site on said PSA.
A kit for determining the presence of free PSA in a test sample comprising:
- a) an antibody or fragment thereof which specifically binds to a peptide comprising an amino acid sequence of approximately 10-20 residues wherein said sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids non-identical to the amino acid sequence of hk2, wherein said peptide is ABT6and wherein said antibody of fragment thereof has been produced in response to said peptide or antigen;
- and
- b) labeled free PSA.
Dependencies are inferred from the claim text.